Company intelligence / Profile preview

Azimuth Biologics

Syracuse, New York, United Statesazimuthbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Azimuth Biologics, founded in April 2023 as a SUNY Upstate Medical University spinout, develops monoclonal antibody therapies for the prevention and treatment of infectious diseases. The company has been recognized as an emerging innovator but has not yet reported clinical results or advanced to human trials.[1][8]

The company was a finalist at the CNY Biotech Accelerator Innovation Pitch Competition in late October 2024.[8]

Therapeutic areas: OtherInfectious Diseases
Modalities: Monoclonal antibodies (mAbs)[1][3][8]
Industry: Biotech

Partnerships

SUNY Upstate Medical University[1]Walter Reed Army Institute of Research[1]Central New York Biotech Accelerator[1]

Beyond the preview

Go deeper on Azimuth Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Azimuth Biologics.

Explore the full profile